Vaccination considerations in the asplenic patient

References Papers of special note have been highlighted as: • of interest

• Morris DH, Bullock FD. The importance of the spleen in resistance to infection. Ann. Surg.70, 513–522 (1919).
   PubMedGoogle Scholar
• King H, Schumacher HB. Splenic studies: susceptibility to infection after splenectomy in infancy. Ann. Surg.136, 239–242 (1952).
   PubMed Web of Science ®Google Scholar
• Eichner ER. Splenic function: normal, too much and too little. Am. J. Med.66, 311–320 (1979).
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J, Kaiser G et al. The value of partial splenic autotransplantation in patients with portal hypertension. Arch. Surg.137, 89–93 (2002).
   PubMedGoogle Scholar
• Vitharsson G, Jonsdottir I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis.170(3), 592–599 (1994).
   PubMed Web of Science ®Google Scholar
• Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin. Microbiol. Infect.7(12), 657–660 (2001).
   PubMed Web of Science ®Google Scholar
• Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among postsplenectomy patients. J. Infection.43, 182–186 (2001).
   PubMed Web of Science ®Google Scholar
• Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J. Clin. Pathol.54, 214–218 (2001).
   PubMed Web of Science ®Google Scholar
• Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease. MMWR46(RR-8), 1–19 (1997).
   PubMedGoogle Scholar
• Hathaway JM, Harley RA, Self S, Schiffman G, Virella G. Immunological function in post-traumatic splenosis. Clin. Immunol. Immunopathol.74(2), 143–150 (1995).
   PubMedGoogle Scholar
• Brigden ML, Pattullo A, Brown G. Pneumococcal vaccine administration associated with splenectomy: the need for improved education, documentation, and the use of a practical checklist. Am. J. Hematol.65(1), 25–29 (2000).
   PubMed Web of Science ®Google Scholar
• Ejstrud P, Hansen JB, Andreasen DA. Prophylaxis against pneumococcal infection after splenectomy: a challenge for hospitals and primary care. Eur. J. Surg.163(10), 733–738 (1997).
   PubMedGoogle Scholar
• Kind EA, Craft C, Fowles JB, McCoy CE. Pneumococcal vaccine administration associated with splenectomy: missed opportunities. Am. J. Infect. Control26(4), 418–422 (1998).
   PubMed Web of Science ®Google Scholar
• Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J. Infect.35(3), 289–294 (1997).
   PubMed Web of Science ®Google Scholar
• Shatz DV. Vaccination practices among North American trauma surgeons in splenectomy for trauma. J. Trauma.53(5), 950–956 (2002).
   PubMedGoogle Scholar
• Barringer M, Meredith W, Starch M et al. Effect of anesthesia and splenectomy on antibody response to pneumococcal polysaccharide immunization. Am. Surg.48, 628–633 (1982).
   PubMed Web of Science ®Google Scholar
• Caplan ES, Boltansky H, Snyder MJ et al. Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J. Trauma.23, 801–805 (1983).
   PubMedGoogle Scholar
• Nielsen SV, Sorenson UBS, Hendrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb. Pathog.14, 299–305 (1993).
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol.4, 415–422 (1997).
   PubMedGoogle Scholar
• Vernacchio L, Romero-Steiner S, Martinez JE et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J. Infect. Dis.181, 1162–1166 (2000).
   PubMed Web of Science ®Google Scholar
• Shatz DV, Schinsky MF, Pais LB et al. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J. Trauma.44, 760–766 (1998).
   PubMedGoogle Scholar
• Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM. Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J. Trauma.53(6), 1037–1042 (2002).
   PubMedGoogle Scholar
• Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol. Infect.119, 167–174 (1997).
   PubMed Web of Science ®Google Scholar
• Vella PA, McLean AA, Woodhour AF, Weibel RE, Hilleman MR. Persistence of pneumococcal antibodies in human subjects following vaccination (40891). Proc. Soc. Exper. Biol. Med.164, 435–438 (1980).
   PubMed Web of Science ®Google Scholar
• Konradsen HB, Pedersen FK, Henrichsen J. Pneumococcal revaccination of splenectomized children. Pediatr. Infect. Dis. J.9, 258–263 (1990).
   PubMed Web of Science ®Google Scholar
• Konradsen HB, Nielsen JL, Pedersen FK, Henrichsen J. Antibody persistence in splenectomized adults after pneumococcal vaccination. Scand. J. Infect. Dis.22, 725–727 (1990).
   PubMed Web of Science ®Google Scholar
• Goebel W, Avery OT. Chemoimmunological studies conjugated carbohydrate proteins: I – the synthesis of p-aminophenol -glucoside, p-aminophenol-galactoside and their coupling with serum globulin. J. Exp. Med.50, 521–533 (1929).
   PubMedGoogle Scholar
• Butler JC, Breiman RF, Campbell JF et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA270(15), 1826–1831(1993).
   PubMed Web of Science ®Google Scholar
• Hanna JN, Wenck DJ, Murphy DN. Three fatal pneumococcal polysaccharide vaccine failures. Med. J. Aust.173(6), 305–307 (2000).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Parkinson AJ, Bulkow L et al. Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls. Am. J. Med.95(6), 589–594 (1993).
   PubMed Web of Science ®Google Scholar
• Begemann M, Policar M. Pneumococcal vaccine failure in an HIV-infected patient with fatal pneumococcal sepsis and HCV-related cirrhosis. Mt Sinai J. Med.68(6), 396–399 (2001).
   PubMedGoogle Scholar
• French N, Moore M, Haikala R, Kayhty H, Gilks CF. A case-controlled study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J. Infect. Dis.190(4), 707–712 (2004).
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Musher DM, Cetron MS et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis.29(2), 281–288 (1999).
   PubMed Web of Science ®Google Scholar
• Bolan G, Broome CV, Facklam RR et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann. Int. Med.104(1), 1–6 (1986).
   PubMed Web of Science ®Google Scholar
• Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic hosts. Infect. Dis. Clin. N. America15, 551–565 (2001).
   PubMed Web of Science ®Google Scholar
• Working Party of the British Committee for Standards in Hematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absent of dysfunctional spleen. Br. Med. J.312, 430–434 (1996).
   PubMed Web of Science ®Google Scholar
• Spickett GP, Bullimore J, Wallis J, Smith S, Saunders P. Northern region asplenia register – analysis of first 2 years. J. Clin. Pathol.52(6), 424–429 (1999).
   PubMed Web of Science ®Google Scholar
• Landgren O, Bjorkholm M, Konradsen HB et al. A prospective study on response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin’s lymphoma. J. Intern. Med.255(6), 664–673 (2004).
   PubMed Web of Science ®Google Scholar
• Konradsen HB, Pedersen FK, Henrichsen J. Pneumococcal revaccination of splenectomized children. Pediatr. Infect. Dis. J.9(4), 258–263 (1990).
   PubMed Web of Science ®Google Scholar
• Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and H. influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol. Infect.119, 167–174 (1997).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Hansen J et al. Postlicensure evaluation of the effectiveness of 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.20(12), 1105–1107 (2001).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics106(20), 362–366 (2000).
   PubMed Web of Science ®Google Scholar
• Epidemiology and prevention of vaccine-preventable diseases. Satellite broadcast, session II, Centers for Disease Control and Prevention, February 26 (2004).
   Google Scholar
• Nurkka A, Joensuu J, Henckaerts I et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide–protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J.23(11), 1008–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Bisgard KM, Kao A, Leake J et al. Hemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg. Infect. Dis.4, 229–237 (1998).
   PubMed Web of Science ®Google Scholar
• Recommendations of the Advisory Committee on Immunization Practices (ACIP). Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR42(RR-04), 1–12 (1993).
   PubMedGoogle Scholar
• Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J. Infect. Dis.180, 1894–1901 (1999).
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. Kinetics of antibody production to group A and C meningococcal polysaccharide vaccines administered during the first 6 years of life: prospects for routine immunization of infants and children. J. Infect. Dis.140, 690–697 (1979).
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ et al. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA280(19), 1685–1689 (1998).
   PubMed Web of Science ®Google Scholar
• Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of Group A Neisseria meningitidis followed for 3 years in infants and children. J. Infect. Dis.142, 861–868 (1980).
   PubMed Web of Science ®Google Scholar
• Zangwill KM, Stout RW, Carlone GM et al. Duration of antibody response after meningococcal polysaccharide vaccination in US airforce personnel. J. Infect. Dis.169, 847–852 (1994).
   PubMed Web of Science ®Google Scholar
• Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR49(RR-07), 1–10 (2000).
   PubMedGoogle Scholar
• Cano R, Larrauri A, Mateo S et al. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill.9(7), Epub ahead of print (2004).
   Google Scholar
• MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA283(21), 2795–2801 (2000).
   PubMed Web of Science ®Google Scholar
• Peitzman AB, Heil B, Rivera L et al. Blunt splenic injury in adults: multi-institutional study of the Eastern Association for the Surgery of Trauma. J. Trauma.49(2), 177–189 (2000).
   PubMedGoogle Scholar
• Hagiwara A, Yukoka T, Ohta S et al. Nonsurgical management of patients with blunt splenic injury: efficacy of transcatheter arterial embolization. AJR167(1), 159–166 (1996).
   PubMed Web of Science ®Google Scholar
• Haan J, Biffl W, Knudson MM et al. Splenic embolization revisited: a multicenter review. J. Trauma.56(3), 542–547 (2004).
   PubMedGoogle Scholar
• Resende V, Petroianu A. Functions of the splenic remnant after subtotal splenectomy for treatment of severe splenic injuries. Am. J. Surg.185, 311–315 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J, Kaiser GM et al. The value of partial splenic autotransplantation in patients with portal hypertension. Arch. Surg.137, 89–93 (2002).
   PubMedGoogle Scholar
• Leemans R, Manson W, Snijder JAM et al. Immune response capacity after human splenic autotransplantation. Restoration of response to individual pneumococcal vaccine subtypes. Ann. Surg.229(2), 279–285 (1999).
   PubMed Web of Science ®Google Scholar